Aerovate Therapeutics Inc (AVTE)
$2.68
$-91.12
(-97.14%)
As on 28-Apr-2025 16:28EDT
Market cap
$78 Mln
Revenue (TTM)
$0 Mln
P/E Ratio
--
P/B Ratio
35.6
Div. Yield
0 %
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
$0 Mln
-
ROE
-0.6 %
-
ROCE
-- %
-
Industry P/E
--
-
EV/EBITDA
-9.3
-
Debt to Equity
0
-
Book Value
$--
-
EPS
$--
-
Face value
--
-
Shares outstanding
28,985,000
5 Years Aggregate
CFO
$-133.94 Mln
EBITDA
$-170.35 Mln
Net Profit
$-162.36 Mln
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Aerovate Therapeutics Inc (AVTE)
| -97.1 | -97.0 | -97.0 | -99.6 | -82.4 | -- | -- |
|
BSE Sensex*
| -9.3 | 2.0 | 0.1 | -5.7 | 6.6 | 8.0 | 11.2 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2024
|
2023
|
2022
|
|---|---|---|---|
|
Aerovate Therapeutics Inc (AVTE)
| -88.1 | -22.8 | 148.5 |
|
S&P Small-Cap 600
| 7.0 | 13.9 | -17.4 |
|
BSE Sensex
| 8.1 | 18.7 | 4.4 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Peers
View DetailsCompany |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Aerovate Therapeutics Inc (AVTE)
|
2.7 | 77.7 | 0.0 | -49.0 | -- | -63 | -- | 35.6 |
| 0.0 | 7.9 | 8.1 | -73.1 | -703.2 | -276.4 | -- | 0.2 | |
| 0.5 | 1.6 | 1.7 | -34.6 | -3,246.1 | -215.6 | -- | 0.2 |
Shareholding Pattern
View DetailsAbout Aerovate Therapeutics Inc (AVTE)
Aerovate Therapeutics, Inc., a biopharmaceutical company, engages in the treatment of pulmonary arterial hypertension in the United States. Aerovate Therapeutics, Inc., was incorporated in 2018 and is headquartered in Waltham, Massachusetts.
-
CEO & Director
Mr. Timothy P. Noyes M.B.A.
-
CEO & Director
Mr. Timothy P. Noyes M.B.A.
-
Headquarters
Waltham, MA
-
Website
Value Research Ratings
Our rating system has guided millions of investors in the past 20 years.
FAQs for Aerovate Therapeutics Inc (AVTE)
What is the current share price of Aerovate Therapeutics Inc (AVTE) Today?
The share price of Aerovate Therapeutics Inc (AVTE) is $2.68 (NASDAQ) as of 28-Apr-2025 16:28 EDT. Aerovate Therapeutics Inc (AVTE) has given a return of -82.39% in the last 3 years.
What is the current PB & PE ratio of Aerovate Therapeutics Inc (AVTE)?
Since, TTM earnings of Aerovate Therapeutics Inc (AVTE) is negative, P/E ratio is not available.
The P/B ratio of Aerovate Therapeutics Inc (AVTE) is 35.57 times as on 28-Apr-2025, a 759 premium to its peers’ median range of 4.14 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2024
|
--
|
--
|
|
2023
|
--
|
--
|
|
2022
|
--
|
--
|
|
2021
|
--
|
--
|
|
2020
|
--
|
--
|
What is the 52 Week High and Low of Aerovate Therapeutics Inc (AVTE)?
The 52-week high and low of Aerovate Therapeutics Inc (AVTE) are Rs -- and Rs -- as of 20-Jun-2026.
What is the market cap of Aerovate Therapeutics Inc (AVTE)?
Aerovate Therapeutics Inc (AVTE) has a market capitalisation of $ 78 Mln as on 28-Apr-2025. As per SEBI classification, it is a Small Cap company.
Should I invest in Aerovate Therapeutics Inc (AVTE)?
Before investing in Aerovate Therapeutics Inc (AVTE), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.